Stockholm, January 30, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the application for manufacturing and marketing approval for lecanemab ...
Stockholm, January 27, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the European Medicines Agency (EMA) has accepted a marketing ...
Stockholm, January 19, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Chairman of the Board of Directors, Wenche Rolfsen, has informed the Nomination Committee that ...
Stockholm, January 16, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab ...
Stockholm, January 11, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application (MAA) for ...
Stockholm, January 6, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and ...
Stockholm, November 30, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during November issued 71, 586 B shares for delivery ...
Stockholm, November 30, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory ...
Stockholm, November 30, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory ...
Stockholm, October 25, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been made aware that the company’s two founders and main shareholders, Lars Lannfelt ...
Groundbreaking results for lecanemab in Phase 3 study in early Alzheimer's disease Events during the third quarter 2022 Lecanemab showed positive results in the pivotal Phase ...
Stockholm, Sweden, October 18, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 5, 2022, adopted an instruction regarding the appointment ...
Stockholm, September 28, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced positive topline results for the large global Phase 3 confirmatory ...
FDA grants priority review for lecanemab marketing application Events during the second quarter 2022 Eisai completed the rolling submission of lecanemab for treatment of early Alzheimer’s ...
Stockholm, July 6, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration (FDA) has accepted ...
Stockholm, May 10, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have completed the rolling submission to the U.S. ...
Stockholm, Sweden, May 5, 2022 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. Due to Covid-19, the Annual General Meeting ...
Decision on marketing approval for lecanemab is approaching Events during the first quarter 2022 Eisai commenced submission of lecanemab data in Japan for a prior ...
Stockholm, April 20, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has announced that the company’s partner AbbVie has decided to terminate its collaboration with ...
Stockholm March 31, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2021 Annual Report has been published. ...
Stockholm March 9, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals ...
Stockholm, March 4, 2022 - BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) ...
Stockholm, December 24, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for ...
Stockholm, Sweden, November 1, 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 6, 2021, adopted an instruction regarding the appointment ...
Eisai initiates Biologics License Application of lecanemab in the US earlier than expected Events during the third quarter 2021 Eisai has initiated a rolling submission for ...
Stockholm, September 28, 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that they have initiated a rolling submission to the U.S. ...
FDA grants Breakthrough Therapy designation for lecanemab Events during the second quarter 2021 The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for lecanemab ...
Stockholm, 23 June 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has granted ...
Stockholm, Sweden, May 6, 2021 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. Due to the continued spread of the ...
The shareholders in BioArctic AB (publ), corporate identity number 556601-2679 (the “Company” or “BioArctic”) are hereby summoned to the Annual General Meeting to be held on ...
Stockholm March 31, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2020 Annual Report has been published.
Stockholm February 12, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals ...
BioArctic presents Nomination Committee Stockholm, Sweden, October 13, 2020 – BioArctic's Annual General Meeting on May 7, 2020, adopted an instruction regarding the appointment of the Nomination ...
Continued performance according to plan Key events during the second quarter 2020 BioArctic communicated that the mechanism of action for the AD1801 antibody project is ...
Stockholm, Sweden, July 1, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June ...
Stockholm, Sweden, May 26, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that seven members of the company's Board and management today have ...
Stockholm, Sweden, May 7, 2020 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. The following resolutions were adopted. Adoption ...
Operations performing according to plan Key events during the first quarter 2020 As of today, BioArctic has not experienced any noteworthy disruptions to its operations ...
Stockholm, Sweden, April 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2020 ...
The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, 7 May 2020 More information about ...
Stockholm April 2, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for the 2019 has been published in ...
Stockholm March 24, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Nomination Committee for BioArctic AB provides the following proposals for ...
Stockholm, Sweden, December 17, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the initiation of a research collaboration with Eisai aimed at ...
Stockholm, Sweden, December 5, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that data from the ongoing BAN2401 Phase 2b open-label extension study ...
Stockholm, Sweden, November 18, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the results of an interim analysis of a Phase 1/2 study ...
Stockholm, Sweden, November 5, 2019 – The Annual General Meeting of BioArctic AB on May 9, 2019, adopted instructions regarding the appointment of the Nomination Committee. ...
BioArctic: Strong continued progress year to date Summary of key events for the third quarter 2019 BioArctic and Eisai presented new data regarding BAN2401 at ...
Stockholm, Sweden, May 20, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR ...
Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting 2019. The following resolutions were adopted:
Stockholm, Sweden, April 16, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2018 fiscal year has been ...
The shareholders in BioArctic AB (publ), corporate identity number 556601-2679 (”the Company”) are hereby summoned to the Annual General Meeting to be held on May 9, ...
Stockholm, Sweden, March 22, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory ...
Stockholm, Sweden, March 21, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) comments on the decision today by Nasdaq Stockholm to halt trading in BioArctic ...
Stockholm, Sweden, March 13, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the ...
Stockholm, Sweden, March 7, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informs that Eisai today announced the timelines for the single confirmatory Phase 3 ...
Stockholm, Sweden, February 13, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase ...
ABBV-0805 is being evaluated as a potential disease modifying treatment for Parkinson’s Disease Stockholm, Sweden, February 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA ...
Stockholm, Sweden, February 4, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai stated at their Q3 FY2018 Financial Results Meeting on ...
Stockholm, Sweden, December 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. ...
Stockholm, Sweden, November 12, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been awarded a grant from EU’s research and innovation program Horizon 2020. ...
Stockholm, Sweden, November 6, 2018 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 15, 2018 the members of ...
Stockholm, Sweden, November 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a Notice of Option Exercise ...
Stockholm, Sweden, October 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) previously announced on July 6, 2018 the positive topline results from the clinical ...
Stockholm, Sweden, October 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to ...
Stockholm, Sweden, October 3, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to ...
Stockholm, Sweden, September 13, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has signed a research agreement with Brain Biomarker Solutions in Gothenburg AB (BBS). ...
Stockholm, Sweden, September 3, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that the company has signed an expanded research collaboration agreement with ...
Stockholm, Sweden, August 7, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has in collaboration with Eisai identified a completely new biological target, which provides ...
Stockholm, Sweden, July 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced on July 6 the positive topline results from the clinical Phase ...
Stockholm, Sweden, July 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B). As previously announced, the BAN2401 Phase 2b clinical study results will be presented ...
Stockholm, Sweden, July 10, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by Fimea, the Finnish Medicines ...
Stockholm, Sweden, July 10, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces today the results of the BAN2401 Phase 2b clinical study (ClinicalTrials.gov identifier ...
The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in early Alzheimer’s disease demonstrated statistically significant and dose-dependent slowing in ...
Stockholm, Sweden, June 27, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that professor Lars Lannfelt resumes his employment in the company as ...
Stockholm, Sweden, May 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has signed an extended research collaboration agreement with ...
Continued progress of the project portfolio January - March 2018 Net sales for the period amounted to SEK 52.3 million (26.2) Operating profit amounted to SEK ...
Stockholm, Sweden, April 25, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the inclusion of patients with complete spinal cord injury in ...
Stockholm, Sweden, April 24, 2018 – BioArctic AB (publ.) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2017 fiscal year has ...
The shareholders in BioArctic AB (publ), corporate identity number 556601-2679, (”the Company”) are hereby summoned to the Annual General Meeting to be held on Tuesday, ...
Stockholm, Sweden, March 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Norwegian Medicines Agency ...
Stockholm, Sweden, March 19, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) issued a notification to grant ...
Stockholm, Sweden, February 21, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Estonian State Agency ...
Successful IPO and continued positive result for BioArctic. October – December 2017. Net sales for the period amounted to SEK 51.0 million (94.4). Operating profit amounted ...
Stockholm, Sweden, February 5, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report 2017 for the period January – ...
Stockholm, Sweden, February 2, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US Patent and Trademark Office (USPTO) published an Issue ...
Criteria for success at 12 month interim analysis of ADCOMS not met Study to remain blinded per protocol until final readout of comprehensive 18 month data
Stockholm, Sweden, November 9, 2017 – According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 31, 2017 the members of ...
BioArctic listed on Nasdaq Stockholm Mid Cap. July - September 2017- Net sales for the period amounted to SEK 31.5 million (1.2). Operating profit amounted to SEK ...
Stockholm, Sweden, October 31, 2017 – BioArctic AB (publ) (“BioArctic” or the “Company” ) today announced that the number of shares and votes in BioArctic has ...
Stockholm, Sweden, October 13, 2017 – BioArctic AB (publ) (Nasdaq Stockholm:BIOA B) today announced that the European Patent Office (EPO) has decided to grant a European ...